PowerPoint Presentation ABSTRACT BACKGROUND: FLX475 (tivumecirnon, or TIVU) is a selective CCR4 antagonist designed to block the recruitment of immunosuppressive regulatory T cells (Treg) into the tumor microenvironment The FLX475-02 trial (NCT03674567) is a phase 1 2 study of FLX475 as monotherapy and in combination with pembrolizumab in subjects with advanced cancer Early encouraging data on the biologic effects
Clinical and molecular effects of oral CCR4 . . . - RAPT Therapeutics This study was sponsored by RAPT Therapeutics, Inc The Sponsor would like to thank contribu-tors to the program at RAPT Therapeutics, Inc , study investigators, site staff, and the study participants for their support of and con-tributions to the trial
Biological activity of FLX475, an oral CCR4 . . . - RAPT Therapeutics FLX475 is a potent and selective CCR4 antagonist, designed to block immunosuppressive regulatory T cell (Treg) migration into the tumor microenvironment (TME), which has the potential to overcome immune resistance and broaden clinical efficacy to a variety of conventional and immunotherapy-based approaches In a recent interim clinical update from the ongoing FLX475-02 Phase 1 2 trial
investors. rapt. com Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) See Instruction 10
investors. rapt. com Check this box if no longer subject to Section 16 Form 4 or Form 5 obligations may continue
A combined mregDC and Treg signature associates . . . - RAPT Therapeutics We thank our colleagues at RAPT Therapeutics and scientific advisors for helpful suggestions and discussion This study is in collaboration with Merck Sharp Dohme LLC, a subsidiary of Merck Co , Inc , Rahway, NJ, USA st Spatial profiling was performed (n=2, tumors) with a multicolor IF panel on FFPE tumors